Imetelstat has limited single-agent activity in the AML cell

Imetelstat is a 13-mer oligonucleotide that specifically

*in vitro*
imetelstat enhances inhibition of cell viability

methyltransferase inhibitors (DNMTis) that are currently

show activity in patients with essential thrombocythemia

potent first-in-class competitive inhibitor of telomerase
targets the RNA template of human telomerase and is a

links between overexpression and hypermethylation of the

(hTERT).

(hTERT).

the catalytic unit of human telomerase reverse transcriptase

Expression

(European Money
targets the RNA template of human telomerase and is a

links between overexpression and hypermethylation of the

ocytes had greater viability reductions in response to either DAC or AZA, as expected based on

viability at 72 hours post dose (solid bars) with the 1

批复 treatment with DAC (top) or AZA (bottom). Following washout removal of DNMTi at 72

Cells were treated with DAC (top) or AZA (bottom) every 24 hours for 72 hours (solid bars),

Cells were pretreated once every 24 hours for 5 days (Panel A) with either dose

hypomethylation, a follow-up study with an optimal dosing schedule was conducted.

and cell proliferation had recovered by 2 weeks in cells with high hTERT expression

— Apoptosis increased in a dose-dependent manner with imetelstat treatment as well


Poster presented at the American Association for Cancer Research Annual Meeting 2016, April 16-20, 2016, New Orleans, LA.

with funding from Janssen Global Services, LLC (Raritan, NJ).

ACKNOWLEDGMENTS

Joshua Rusbuldt, Jacqueline Russolari, Aleksandra Rizo, Fei Huang

Janssen Research & Development, LLC

Sponsored by Janssen Global Services, LLC

REFERENCES


3. Tamara Fink, PhD, of PAREXEL (Hackensack, NJ), with funding from Janssen Global Services, LLC (Raritan, NJ).


Poster presented at the American Association for Cancer Research Annual Meeting 2016, April 16-20, 2016, New Orleans, LA.

with funding from Janssen Global Services, LLC (Raritan, NJ).

ACKNOWLEDGMENTS

Joshua Rusbuldt, Jacqueline Russolari, Aleksandra Rizo, Fei Huang

Janssen Research & Development, LLC

Sponsored by Janssen Global Services, LLC

REFERENCES
